Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.15
ZTS's Cash to Debt is ranked lower than
91% of the 768 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.60 vs. ZTS: 0.15 )
Ranked among companies with meaningful Cash to Debt only.
ZTS' s Cash to Debt Range Over the Past 10 Years
Min: 0.1  Med: 0.17 Max: N/A
Current: 0.15
Equity to Asset 0.16
ZTS's Equity to Asset is ranked lower than
94% of the 708 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. ZTS: 0.16 )
Ranked among companies with meaningful Equity to Asset only.
ZTS' s Equity to Asset Range Over the Past 10 Years
Min: 0.12  Med: 0.19 Max: 0.69
Current: 0.16
0.12
0.69
Interest Coverage 7.94
ZTS's Interest Coverage is ranked lower than
69% of the 468 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 23.86 vs. ZTS: 7.94 )
Ranked among companies with meaningful Interest Coverage only.
ZTS' s Interest Coverage Range Over the Past 10 Years
Min: 2.3  Med: 7.55 Max: 22.42
Current: 7.94
2.3
22.42
F-Score: 7
Z-Score: 3.73
M-Score: -2.37
WACC vs ROIC
8.42%
18.44%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 22.86
ZTS's Operating margin (%) is ranked higher than
85% of the 712 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.72 vs. ZTS: 22.86 )
Ranked among companies with meaningful Operating margin (%) only.
ZTS' s Operating margin (%) Range Over the Past 10 Years
Min: -4.53  Med: 15.74 Max: 19.73
Current: 22.86
-4.53
19.73
Net-margin (%) 7.83
ZTS's Net-margin (%) is ranked higher than
56% of the 714 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.02 vs. ZTS: 7.83 )
Ranked among companies with meaningful Net-margin (%) only.
ZTS' s Net-margin (%) Range Over the Past 10 Years
Min: -3.62  Med: 7.11 Max: 12.18
Current: 7.83
-3.62
12.18
ROE (%) 31.95
ZTS's ROE (%) is ranked higher than
93% of the 745 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.02 vs. ZTS: 31.95 )
Ranked among companies with meaningful ROE (%) only.
ZTS' s ROE (%) Range Over the Past 10 Years
Min: 11.26  Med: 20.30 Max: 51.8
Current: 31.95
11.26
51.8
ROA (%) 5.39
ZTS's ROA (%) is ranked higher than
60% of the 772 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.65 vs. ZTS: 5.39 )
Ranked among companies with meaningful ROA (%) only.
ZTS' s ROA (%) Range Over the Past 10 Years
Min: 4.68  Med: 7.86 Max: 8.87
Current: 5.39
4.68
8.87
ROC (Joel Greenblatt) (%) 27.91
ZTS's ROC (Joel Greenblatt) (%) is ranked higher than
70% of the 765 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.79 vs. ZTS: 27.91 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ZTS' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 24.65  Med: 29.52 Max: 34.3
Current: 27.91
24.65
34.3
Revenue Growth (3Y)(%) 3.10
ZTS's Revenue Growth (3Y)(%) is ranked lower than
58% of the 605 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. ZTS: 3.10 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ZTS' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 3.55 Max: 8.4
Current: 3.1
0
8.4
EBITDA Growth (3Y)(%) -2.80
ZTS's EBITDA Growth (3Y)(%) is ranked lower than
70% of the 553 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.20 vs. ZTS: -2.80 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ZTS' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 9.30 Max: 35.8
Current: -2.8
0
35.8
EPS Growth (3Y)(%) -8.20
ZTS's EPS Growth (3Y)(%) is ranked lower than
71% of the 509 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.00 vs. ZTS: -8.20 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ZTS' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 12.55 Max: 66
Current: -8.2
0
66
» ZTS's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-08-04)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

ZTS Guru Trades in Q2 2015

Richard Perry 2,000,000 sh (New)
Steven Cohen 4,246,900 sh (+2882.37%)
Paul Tudor Jones 30,630 sh (+248.07%)
Louis Moore Bacon 95,000 sh (+72.73%)
Mario Gabelli 695,142 sh (+13.07%)
Ruane Cunniff 151,149 sh (+8.01%)
Pioneer Investments 2,881,279 sh (+0.06%)
Bill Ackman 41,823,145 sh (unchged)
Caxton Associates Sold Out
John Keeley 60,874 sh (-1.59%)
Jim Simons 1,510,800 sh (-17.12%)
Vanguard Health Care Fund 5,115,837 sh (-17.16%)
George Soros 2,744,635 sh (-33.17%)
First Eagle Investment 508,942 sh (-37.97%)
Robert Olstein 20,000 sh (-85.82%)
» More
Q3 2015

ZTS Guru Trades in Q3 2015

Jana Partners 3,894,424 sh (New)
Paul Tudor Jones 48,955 sh (+59.83%)
Richard Perry 3,000,200 sh (+50.01%)
George Soros 3,520,997 sh (+28.29%)
Louis Moore Bacon 115,000 sh (+21.05%)
Pioneer Investments 3,288,456 sh (+14.13%)
Steven Cohen 4,788,800 sh (+12.76%)
Ruane Cunniff 156,094 sh (+3.27%)
Bill Ackman 41,823,145 sh (unchged)
Robert Olstein Sold Out
First Eagle Investment Sold Out
John Keeley 58,474 sh (-3.94%)
Vanguard Health Care Fund 4,804,337 sh (-6.09%)
Mario Gabelli 615,801 sh (-11.41%)
Jim Simons 886,200 sh (-41.34%)
» More
Q4 2015

ZTS Guru Trades in Q4 2015

Pioneer Investments 3,457,394 sh (+5.14%)
Bill Ackman 41,823,145 sh (unchged)
Louis Moore Bacon Sold Out
Richard Perry Sold Out
Jana Partners Sold Out
Ruane Cunniff 151,537 sh (-2.92%)
Mario Gabelli 592,363 sh (-3.81%)
George Soros 3,386,512 sh (-3.82%)
Steven Cohen 4,414,600 sh (-7.81%)
Paul Tudor Jones 44,407 sh (-9.29%)
Vanguard Health Care Fund 4,251,727 sh (-11.50%)
John Keeley 35,902 sh (-38.60%)
Jim Simons 283,400 sh (-68.02%)
» More
Q1 2016

ZTS Guru Trades in Q1 2016

Louis Moore Bacon 13,808 sh (New)
First Eagle Investment 2,812,702 sh (New)
Joel Greenblatt 96,665 sh (New)
Stanley Druckenmiller 477,900 sh (New)
Robert Olstein 82,000 sh (New)
Jim Simons 1,413,100 sh (+398.62%)
John Keeley 78,974 sh (+119.97%)
Bill Ackman 41,823,145 sh (unchged)
Vanguard Health Care Fund Sold Out
Mario Gabelli 579,052 sh (-2.25%)
Pioneer Investments 3,154,039 sh (-8.77%)
Steven Cohen 3,940,500 sh (-10.74%)
Ruane Cunniff 126,783 sh (-16.34%)
George Soros 2,316,921 sh (-31.58%)
Paul Tudor Jones 12,155 sh (-72.63%)
» More
» Details

Insider Trades

Latest Guru Trades with ZTS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:NAS:MYL, OTCPK:SGIOF, OTCPK:ESALY, OTCPK:TKPYY, NYSE:PRGO, OTCPK:MKGAY, OTCPK:APNHY, OTCPK:MTZPY, NYSE:RDY, OTCPK:TAISF, OTCPK:HKMPF, OTCPK:HLUYY, NYSE:VRX, OTCPK:MDABY, NYSE:MNK, NYSE:TARO, OTCPK:SFOSF, OTCPK:HYPMY, OTCPK:DNPUF, OTCPK:IPSEY » details
Traded in other countries:ZOE.Germany,
Zoetis Inc discovers, develops, manufactures & commercializes animal health medicines & vaccines for livestock & companion animals. Its products include anti-infectives, vaccines, parasiticides, medicated feed additives & other pharmaceutical products.

Zoetis Inc was incorporated in Delaware in July 2012. It is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. It has a diversified business, marketing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals); and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals. The Company organizes and operates its business in two geographic regions: the United States (U.S.) and International. Within each of these operating segments, it offers a diversified product portfolio for both livestock and companion animal customers. The Company directly markets its products in approximately 45 countries across North America, Europe, Africa, Asia, Australia and South America. The Company sells its livestock products directly to a diverse set of livestock producers, including beef and dairy farmers as well as pork, poultry and aquaculture operations, and to veterinarians, third-party veterinary distributors and retail outlets that typically then sell the products to livestock producers. It sells the companion animal products to veterinarians or to third-party veterinary distributors that typically then sell its products to veterinarians, and in each case veterinarians then typically sell its products to pet owners. Its primary competitors include animal health medicines and vaccines companies such as Merck Animal Health, the animal health division of Merck & Co., Inc.; Merial, the animal health division of Sanofi S.A.; Elanco, the animal health division of Eli Lilly and Company; Bayer Animal Health, the animal health division of Bayer AG; and Boehringer Ingelheim Animal Health, the animal health division of Boehringer Ingelheim GmbH. In addition, it competes with hundreds of other animal health product producers throughout the world. It is subject to various federal, state, local and foreign environmental, health and safety laws and regulations.

Ratios

vs
industry
vs
history
P/E(ttm) 62.42
ZTS's P/E(ttm) is ranked lower than
82% of the 535 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.34 vs. ZTS: 62.42 )
Ranked among companies with meaningful P/E(ttm) only.
ZTS' s P/E(ttm) Range Over the Past 10 Years
Min: 27.31  Med: 38.34 Max: 70.37
Current: 62.42
27.31
70.37
Forward P/E 25.38
ZTS's Forward P/E is ranked lower than
74% of the 65 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.67 vs. ZTS: 25.38 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 62.42
ZTS's PE(NRI) is ranked lower than
82% of the 533 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.24 vs. ZTS: 62.42 )
Ranked among companies with meaningful PE(NRI) only.
ZTS' s PE(NRI) Range Over the Past 10 Years
Min: 27.31  Med: 38.34 Max: 70.78
Current: 62.42
27.31
70.78
Price/Owner Earnings (ttm) 159.24
ZTS's Price/Owner Earnings (ttm) is ranked lower than
87% of the 267 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 36.00 vs. ZTS: 159.24 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
ZTS' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 85.88  Med: 161.14 Max: 196.45
Current: 159.24
85.88
196.45
P/B 20.26
ZTS's P/B is ranked lower than
97% of the 734 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.82 vs. ZTS: 20.26 )
Ranked among companies with meaningful P/B only.
ZTS' s P/B Range Over the Past 10 Years
Min: 12.62  Med: 18.28 Max: 24.4
Current: 20.26
12.62
24.4
P/S 4.91
ZTS's P/S is ranked lower than
69% of the 691 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.59 vs. ZTS: 4.91 )
Ranked among companies with meaningful P/S only.
ZTS' s P/S Range Over the Past 10 Years
Min: 3.11  Med: 3.98 Max: 5.25
Current: 4.91
3.11
5.25
PFCF 55.25
ZTS's PFCF is ranked lower than
75% of the 189 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 22.95 vs. ZTS: 55.25 )
Ranked among companies with meaningful PFCF only.
ZTS' s PFCF Range Over the Past 10 Years
Min: 25.69  Med: 46.07 Max: 90.29
Current: 55.25
25.69
90.29
POCF 36.31
ZTS's POCF is ranked lower than
80% of the 254 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.49 vs. ZTS: 36.31 )
Ranked among companies with meaningful POCF only.
ZTS' s POCF Range Over the Past 10 Years
Min: 21.62  Med: 32.40 Max: 41.91
Current: 36.31
21.62
41.91
EV-to-EBIT 34.83
ZTS's EV-to-EBIT is ranked lower than
74% of the 526 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.96 vs. ZTS: 34.83 )
Ranked among companies with meaningful EV-to-EBIT only.
ZTS' s EV-to-EBIT Range Over the Past 10 Years
Min: 20.8  Med: 26.55 Max: 41.7
Current: 34.83
20.8
41.7
EV-to-EBITDA 27.62
ZTS's EV-to-EBITDA is ranked lower than
70% of the 557 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.28 vs. ZTS: 27.62 )
Ranked among companies with meaningful EV-to-EBITDA only.
ZTS' s EV-to-EBITDA Range Over the Past 10 Years
Min: 16.7  Med: 21.20 Max: 32.1
Current: 27.62
16.7
32.1
PEG 3.48
ZTS's PEG is ranked lower than
67% of the 291 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.84 vs. ZTS: 3.48 )
Ranked among companies with meaningful PEG only.
ZTS' s PEG Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 9973.9
Current: 3.48
0
9973.9
Current Ratio 2.84
ZTS's Current Ratio is ranked higher than
58% of the 672 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.40 vs. ZTS: 2.84 )
Ranked among companies with meaningful Current Ratio only.
ZTS' s Current Ratio Range Over the Past 10 Years
Min: 2.08  Med: 2.65 Max: 3.47
Current: 2.84
2.08
3.47
Quick Ratio 1.59
ZTS's Quick Ratio is ranked lower than
57% of the 672 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.78 vs. ZTS: 1.59 )
Ranked among companies with meaningful Quick Ratio only.
ZTS' s Quick Ratio Range Over the Past 10 Years
Min: 1.21  Med: 1.47 Max: 2
Current: 1.59
1.21
2
Days Inventory 298.82
ZTS's Days Inventory is ranked lower than
92% of the 669 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 114.06 vs. ZTS: 298.82 )
Ranked among companies with meaningful Days Inventory only.
ZTS' s Days Inventory Range Over the Past 10 Years
Min: 117.43  Med: 281.16 Max: 289.4
Current: 298.82
117.43
289.4
Days Sales Outstanding 68.69
ZTS's Days Sales Outstanding is ranked higher than
55% of the 625 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 73.75 vs. ZTS: 68.69 )
Ranked among companies with meaningful Days Sales Outstanding only.
ZTS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 71.77  Med: 75.10 Max: 91.07
Current: 68.69
71.77
91.07
Days Payable 44.23
ZTS's Days Payable is ranked lower than
75% of the 586 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 70.79 vs. ZTS: 44.23 )
Ranked among companies with meaningful Days Payable only.
ZTS' s Days Payable Range Over the Past 10 Years
Min: 47.28  Med: 61.65 Max: 110.66
Current: 44.23
47.28
110.66

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.78
ZTS's Dividend Yield is ranked lower than
77% of the 610 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.62 vs. ZTS: 0.78 )
Ranked among companies with meaningful Dividend Yield only.
ZTS' s Dividend Yield Range Over the Past 10 Years
Min: 0.21  Med: 0.68 Max: 1.08
Current: 0.78
0.21
1.08
Dividend Payout 0.47
ZTS's Dividend Payout is ranked higher than
62% of the 376 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.33 vs. ZTS: 0.47 )
Ranked among companies with meaningful Dividend Payout only.
ZTS' s Dividend Payout Range Over the Past 10 Years
Min: 0.22  Med: 0.25 Max: 2.08
Current: 0.47
0.22
2.08
Forward Dividend Yield 0.80
ZTS's Forward Dividend Yield is ranked lower than
78% of the 586 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.69 vs. ZTS: 0.80 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 0.78
ZTS's Yield on cost (5-Year) is ranked lower than
79% of the 707 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.01 vs. ZTS: 0.78 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
ZTS' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0.21  Med: 0.68 Max: 1.08
Current: 0.78
0.21
1.08
3-Year Average Share Buyback Ratio 0.20
ZTS's 3-Year Average Share Buyback Ratio is ranked higher than
84% of the 424 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.40 vs. ZTS: 0.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ZTS' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -0.1  Med: 0.00 Max: 0
Current: 0.2
-0.1
0

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 1.24
ZTS's Price/Median PS Value is ranked lower than
60% of the 662 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.09 vs. ZTS: 1.24 )
Ranked among companies with meaningful Price/Median PS Value only.
ZTS' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.8  Med: 0.99 Max: 1.28
Current: 1.24
0.8
1.28
Earnings Yield (Greenblatt) (%) 2.80
ZTS's Earnings Yield (Greenblatt) (%) is ranked lower than
53% of the 745 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. ZTS: 2.80 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ZTS' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 2.4  Med: 3.80 Max: 4.8
Current: 2.8
2.4
4.8

More Statistics

Revenue (TTM) (Mil) $4,825
EPS (TTM) $ 0.76
Beta1.05
Short Percentage of Float1.10%
52-Week Range $37.73 - 50.39
Shares Outstanding (Mil)496.20

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 4,865 5,135 5,430
EPS ($) 1.86 2.20 2.65
EPS w/o NRI ($) 1.86 2.20 2.65
EPS Growth Rate
(3Y to 5Y Estimate)
20.75%
» More Articles for NYSE:ZTS

Headlines

Articles On GuruFocus.com
Bill Ackman Slashes Position in Zoetis May 20 2016 
All-In-One Screener Finds Week's Largest Insider Trades May 13 2016 
Bill Ackman Comments on Zoetis Inc. May 11 2016 
Ackman Selling Zoetis, But Other Firms Are Jumping In May 10 2016 
Robert Olstein Buys Disney, Zoetis, Michael Kors in the 1st Quarter May 09 2016 
First Eagle Buys Zoetis, T-Mobile, Advance Auto Parts in 1st Quarter May 09 2016 
First Eagle Investment Boosts Stake in American Express May 06 2016 
Highlights of Bill Ackman’s 1st Quarter Pershing Square Conference Call Apr 06 2016 
Bill Ackman’s Fund Falls by Double Digits Again in January Feb 02 2016 
Bill Ackman's 3rd Quarter Letter to Pershing Square Shareholders Dec 21 2015 

More From Other Websites
Post-Brexit, a Dog Is an Investor's Best Friend Jun 30 2016
Zoetis to Host Webcast and Conference Call on Second Quarter 2016 Financial Results Jun 30 2016
Zoetis to Host Webcast and Conference Call on Second Quarter 2016 Financial Results Jun 30 2016
London-Based Marshall Wace LLP Wins Big From Brexit Bets despite Founders Backing Opposing Camps Jun 29 2016
Steve Cohen's London Expansion Unfazed by Brexit Vote Jun 28 2016
Zoetis, Inc. breached its 50 day moving average in a Bearish Manner : ZTS-US : June 27, 2016 Jun 27 2016
Unleashed: A Wave Of Pet-Friendly Services & Innovations Jun 24 2016
Research Report Initiated on Select Healthcare Equities Jun 21 2016
Zoetis, Inc. – Value Analysis (NYSE:ZTS) : June 17, 2016 Jun 17 2016
Can Zoetis (ZTS) Keep the Earnings Streak Alive This Quarter? Jun 17 2016
5 Top ROE Stocks for Improving Your Portfolio Returns Jun 16 2016
A Deeper Look at Three of Our Top Performing Ultimate Stock-Pickers Jun 15 2016
Zoetis, Inc. breached its 50 day moving average in a Bearish Manner : ZTS-US : June 14, 2016 Jun 14 2016
Cramer's Stop Trading: Mattress Firm, Zoetis Jun 10 2016
Zoetis downgraded by Citigroup Jun 10 2016
Zoetis Shares Won't Play Dead Jun 05 2016
4 Long Ideas From the London Value Investor Conference Jun 04 2016
Zoetis Presents New Data on Lokivetmab, a Therapeutic Antibody for Dogs with Atopic Dermatitis, at... May 31 2016
EU agency wants 65 pct cut in farm use of last-ditch antibiotic May 26 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)